ILD Clinical Trial
— SpECC-ILDOfficial title:
Sputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With Interstitial Lung Disease (SpECC-ILD) - a Randomized Controlled Trial
In Interstitial Lung Disease (ILD) there is thickening of lung tissue, which makes it difficult for patients to breathe and get enough oxygen into their bodies. In addition to shortness of breath, daily cough is very common, with 4 out of 5 patients experiencing this symptom. Cough in particular has a major impact on the ability to exercise, be active, and to simply enjoy life. There are many reasons for cough in ILD, and very often there are multiple overlapping causes. It is hard to improve cough in these patients, with available medicines providing limited relief. One explanation for this gap is an incomplete understanding of cough in ILD. To improve patients' cough there is a need to better understand its cause. In other lung diseases, such as asthma, doctors and scientists have used phlegm tests to measure inflammation in the lung, which helps them choose the right medicine for the right patient. This has not been done for ILD, even though it has recently been found that many patients with ILD and everyday cough have abnormal phlegm tests. Using this strategy in ILD could improve patients' cough and quality of life, and possibly even slow progression of the disease.
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | March 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Written informed consent consistent with ICH-GCP and local laws, signed prior to any study procedures being performed - Age >18 years - A clinical diagnosis of ILD with accepted specific diagnoses including: - Idiopathic pulmonary fibrosis (IPF) - Chronic hypersensitivity pneumonitis associated ILD (CHP-ILD) - Connective tissue disease associated ILD (CTD-ILD) - Pneumoconiosis - Daily Cough for at least 8 weeks - Able to produce an adequate sample with sputum induction Exclusion Criteria: - Patients with a diagnosis of systemic sclerosis associated ILD (SSc-ILD) or sarcoidosis - Cause of cough attributed to a known etiology (ex. ACE-inhibitor, uncontrolled gastroesophageal reflux or upper airway cough syndrome, acute viral illness) - Current use of inhaled corticosteroids - Current use of systemic corticosteroids (prednisone equivalent > 20mg/day) - Current use of chronic antibiotics - Airflow obstruction (ie. pre-bronchodilator FEV1/FVC ratio < 0.7) - History of physician-diagnosed asthma - History of emphysema - A history of cholestatic jaundice or hepatic dysfunction associated with prior use of azithromycin - Moderate to severe hepatic dysfunction with a Child Pugh score >10 - Known allergy or hypersensitivity to inhaled corticosteroids or macrolide antibiotics - Corrected QT-interval (QTc) on screening electrocardiogram (ECG) of > 450ms - An established history of untreated atypical mycobacterial infection - A history of hearing impairment, tinnitus, or vertigo - Medication use likely to suppress cough (ex: morphine, gabapentin, amitriptyline) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
McMaster University | St. Joseph's Healthcare Hamilton, Vitalograph |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in hourly cough frequency | The difference in hourly cough frequency over a 24-hour period between baseline and end of study. | 16 weeks | |
Secondary | Change in FEV1 | The difference in forced expiratory volume in 1 second (as obtained by spirometry) between baseline and end of study | 16 weeks | |
Secondary | Change in FVC | The difference in forced vital capacity (as obtained by spirometry) between baseline and end of study | 16 weeks | |
Secondary | Change in Leicester Cough Questionnaire | The difference in LCQ between baseline and end of study | 16 weeks | |
Secondary | Change in King's Brief ILD Questionnaire | The difference in KB-ILD between baseline and end of study | 16 weeks | |
Secondary | Change in sputum total cell count | The difference in sputum total cell count between baseline and end of study | 16 weeks | |
Secondary | Change in sputum neutrophils | The difference in sputum neutrophil percent between baseline and end of study | 16 weeks | |
Secondary | Change in sputum eosinophils | The difference in sputum eosinophil percent between baseline and end of study | 16 weeks | |
Secondary | Adverse events | Adverse events reported by participants | 16 weeks | |
Secondary | Serious adverse events | Serious adverse events reported by participants | 16 weeks | |
Secondary | Completion rates for Bi-weekly LCQ | Rates of completion for bi-weekly LCQ | 16 weeks | |
Secondary | Study medication adherence rate | Rates of adherence to study medications | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04767074 -
A Non-pharmacological Cough Control Therapy
|
N/A | |
Recruiting |
NCT04047667 -
Cone Beam CT Guided Transbronchial Cryobiopsy
|
||
Completed |
NCT03728595 -
Validation of a Predictive Score for HAST
|
||
Terminated |
NCT04311567 -
Effects of Tofacitinib vs Methotrexate on Rheumatoid Arthritis Interstitial Lung Disease
|
Phase 4 | |
Completed |
NCT03336736 -
The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis
|
||
Recruiting |
NCT06280443 -
Sarcopenia in Chronic Lung Diseases
|
||
Active, not recruiting |
NCT06290635 -
Edmonton Dyspnea Inventory- Validation Study
|
||
Recruiting |
NCT05926713 -
Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung Disease
|
N/A | |
Recruiting |
NCT05092035 -
Recognition of Early Pulmonary Structural Changes by Using Real-time High Fidelity Expiratory CO2 Analysis
|
N/A | |
Completed |
NCT04691336 -
Individualized Plan for Improving Adherence to Portable Oxygen Therapy in Patients With Respiratory Pathology
|
N/A | |
Recruiting |
NCT05469555 -
Azithromycin and Oesophageal Function in Respiratory Disease
|
||
Recruiting |
NCT04564183 -
Advancing Prevention of Pulmonary Fibrosis
|
||
Not yet recruiting |
NCT06167811 -
Acute Effect of Whole-body Electrical Stimulation in ILD Patients
|
N/A | |
Not yet recruiting |
NCT06198608 -
Misdiagnosis Between Interstitial Lung Disease and Cardiac Patients
|
||
Completed |
NCT03895931 -
Effect of Inpatient Pulmonary Rehabilitation on Frailty in Candidates for Lung-Transplantation
|
||
Recruiting |
NCT06012500 -
Evaluation of Explanted Lungs by MRI and Biological Assays
|